Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 233,61 € (+0,80 %). Medianen er 237,11 € (+2,31 %).
| Køb |
13 |
| Behold |
18 |
| Sælg |
3 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Quest Diagnostics raises full-year revenue forecast and sees broad-based growth
At the Morgan Stanley Healthcare Conference, Quest Diagnostics reported broad-based momentum and raised its 2026 revenue forecast to 8.3–9.2%. Drivers include higher utilization, increased revenue per requisition, new partnerships (Corewell Health, Fresenius) and a roughly 30% growing consumer business. Management expects operating margin expansion for the full year despite slower growth in H2 due to unenrollments from health exchanges and base effects. Quest plans to update long-term growth and margin targets at a capital markets day in March 2027. » Mere på de.investing.com
Quest Diagnostics hits all-time high of $246.06
Quest Diagnostics stock climbed to a new all-time high of $246.06 and is up about 43% year-to-date. In the second quarter the company beat adjusted EPS of $3.12 (consensus $2.82) and revenue of $3.04 billion and raised its full-year outlook. Truist Securities raised its price target to $250 while maintaining a "hold" rating. An InvestingPro analysis classifies the stock as overvalued but rates the financial situation as "VERY GOOD"; Quest Diagnostics also raised its dividend for the 15th consecutive year. » Mere på de.investing.com
Quest Diagnostics integrates Roche pTau217 blood test and expands AD-Detect with multi‑biomarker test
Quest Diagnostics is adding Roche’s FDA‑cleared Elecsys pTau217 blood test to its AD‑Detect portfolio and plans to offer it to physicians and study partners in Q4 2026. At the same time, Quest will launch its own multi‑biomarker test (Aβ42/40, p‑tau217 and ApoE) at the end of August; using mass spectrometry it generates a score to predict Alzheimer’s pathology and showed only a 10% rate of indeterminate results in studies. The tests will be available through about 2,000 Quest patient service centers as well as physician offices and mobile services, and Quest plans to integrate the pTau217 test into future AD‑Detect lines starting in 2027. » Mere på de.investing.com
Quest Diagnostics hits new all-time high at $240.15
Quest Diagnostics stock reached a new all-time high of $240.15 and is trading near its 52-week high, with a year-to-date gain of about 38% and a market value of $26.35 billion. In Q2 the company beat expectations with adjusted EPS of $3.12 (consensus $2.82) and revenue of $3.04 billion, after which it raised its full-year outlook. InvestingPro currently classifies the stock as overvalued, while Truist Securities raised the price target to $250 and affirmed a "hold" rating. » Mere på de.investing.com
Quest Diagnostics pays quarterly dividend of $0.86
The board of directors of Quest Diagnostics has declared a quarterly cash dividend of $0.86 per share. The dividend will be paid on October 21, 2026 to shareholders of record as of October 6, 2026. Quest Diagnostics provides diagnostic information services in the United States. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 2,73 mia. | 13,94 % |
| Bruttofortjeneste | 919,93 mio. | 13,76 % |
| Nettoresultat | 275,45 mio. | 31,94 % |
| EBITDA | 550,9 mio. | 18,19 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 26,05 mia. € |
Antal aktier | 110,02 mio. |
Højeste/laveste i 52 uger | 238,93 € - 156,11 € |
Udbytteafkast | 1,22 % |
Udbytte TTM | 2,92 € |
Beta | 0,55 |
P/E (PE Ratio) | 25,50 |
PEG (PEG Ratio) | 1,43 |
K/I (PB Ratio) | 3,74 |
P/S (PS Ratio) | 2,41 |
Virksomhedsprofil
Quest Diagnostics Incorporated leverer diagnostiske tests, information og services i USA og internationalt. Virksomheden udvikler og leverer diagnostiske informationsydelser, såsom rutineprøver, ikke-rutinemæssige og avancerede kliniske tests, anatomisk patologi-undersøgelser og andre diagnostiske informationsydelser. Den tilbyder diagnostiske informationsydelser primært under Quest Diagnostics-varemærket samt under mærkerne AmeriPath, Dermpath Diagnostics, ExamOne og Quanum til patienter, klinikere, hospitaler, uafhængige leveringsnetværk, sundhedsforsikringsselskaber, arbejdsgivere, direkte kontraktenheder og accountable care organisations gennem et netværk af laboratorier, patientserviceCentre, flebotomister i lægepraksis, callcentre og mobile paramedicinere, sygeplejersker og andre sundheds- og wellnessprofessionelle. Virksomheden leverer også risikovurderingsydelser til livsforsikringsbranchen samt robuste it-løsninger til sundhedsorganisationer og klinikere. Quest Diagnostics Incorporated blev grundlagt i 1967 og har hovedkvarter i Secaucus, New Jersey.
| Navn | Quest Diagnostics |
| CEO | James E. Davis |
| Hjemsted | Secaucus,
nj USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudbydere og -tjenester |
| Børsnotering | 17.12.1996 |
| Medarbejdere | 57.000 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | DGX |
London Stock Exchange | 0KSX.L |
Frankfurt | QDI.F |
Düsseldorf | QDI.DU |
London | 0KSX.L |
SIX | QDI.SW |
München | QDI.MU |